Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

View:
Post by Johnandrose22 on Mar 25, 2021 7:07am

Good News

The company has launched a sixth clinical site in San Antonio Texas. Patient #16 has been treated.
Comment by Longholder99 on Mar 25, 2021 7:17am
These American mega sites could treat all 9 required in about 2 weeks. More notoriety in a big market as US results surface. All good stuff.
Comment by 99942Apophis on Mar 25, 2021 7:49am
Longholder99 wrote These American mega sites could treat all 9 required in about 2 weeks. More notoriety in a big market as US results surface. All good stuff. You're not alone in that thought Longholder99, yes and would be comforting to speculate that with 11 clinical study sites and as more vaccinations done on both sides of the border the wheel will be picking up speed. 
Comment by enriquesuave on Mar 25, 2021 8:10am
Looks like they are getting ready to treat those 9 soon " early 2021". IMo   "It is truly uplifting to be working on the details of getting patients enrolled and treated at these sites. Theralase is another step closer in achieving its next milestone of enrolling and treating 9 additional patients in early 2021 to meet the target of 25 patients for potential Breakthrough ...more  
Comment by Oden6570 on Mar 25, 2021 8:16am
Agreed, the light in the tunnel looks a little brighter.
Comment by Johnandrose22 on Mar 25, 2021 8:22am
If my recollection is accurate, with each announcement of a new clinical site launch the company continues to indicate their goal of applying for Breakthrough Designation. This seems to indicate to me that the company remains confident that, not only will they reach 25 treated patients but that their clinical data to date continues to support that application. I anticipate the next set of data ...more  
Comment by fredgoodwinson on Mar 25, 2021 8:35am
Yes the further positive takeaways are that 4 patients should now have received an optimal first dose enabling a start to the drawing of meaningful conclusions in the not too distant future and from what the CEO says that something must and will change very soon on treatments from what still has the appearance of being 1 a month at UHN.   
Comment by Longholder99 on Mar 25, 2021 8:47am
When the American public finds out that a treatment like this exists. They won't take no for an answer. Its just a matter of time and a few well placed NRs before Right to Try takes this through the goal posts. What would you want for your loved one? Endless side effects and marginal efficacy? With an eventual bag hanging down your leg? Or one (or two) and done very effective outpatient ...more  
Comment by jicoop on Mar 25, 2021 9:15am
At least they got into the south west now, and close to one of the best treatment centers in University of Texas MD Anderson Cancer center, so this is promising. Urology San Antonio is the largest urology practice in South Texas with multiple locations offering care for men and women experiencing complications of the urinary system. Their subspecialists develop incredible expertise in different ...more  
Comment by CancerSlayer on Mar 25, 2021 3:43pm
  Agree Fred....I am hoping the FDA ultimately dismisses the previous "unrepresentative" data.  Those patients who were removed (based on the now discarded protocol) negatively biased the data.  Based on the updated protocol, such data would be considered invalid & should also be discarded imo = not included in the final analysis.   Based on other granted BTDs ...more  
Comment by fredgoodwinson on Mar 25, 2021 3:54pm
Absolutely CancerSlayer. For those of us with confidence in this tech recruitment is the key atm and what wouldn’t it do to boost numbers if they had good 90-day data that they could publish on 13 & 14 right now?
Comment by CancerSlayer on Mar 25, 2021 4:22pm
I agree...speedy recruitment is key, especially when on a limited budget.  To publish or not to publish?  It's always a delicate balance between presenting more statistically significant data & presenting more impactful data.  My guess is good 90-day data in at least 6+ US-treated patients will hopefully get us some great news.  JMO.
Comment by fredgoodwinson on Mar 25, 2021 4:48pm
They`ve published Clinical Trial data really very early at times (38 days` after treating P.6 in Phase IB from memory) so it is their call. Just a sense that recruitment is floundering a bit atm and that it`s not just Covid.
Comment by CancerSlayer on Mar 25, 2021 5:30pm
For a novel Ph 1, I'm not too surprised they published early.  A Ph 2 primary endpoint of CR (at any time) simply requires more meaningful data/more time imo.  As for patient accrual, we are still in the relatively early stages for the US trials...I expect we'll be well ahead of Canada in very short order. Though 16 treated patients to date may seem low, we could very well have ...more  
Comment by tamarindo1 on Mar 25, 2021 5:51pm
I agree, I'm an 85 year old 3 pee a night gaffer.
Comment by 99942Apophis on Mar 25, 2021 9:18pm
tamarindo1 wrote I agree, I'm an 85 year old 3 pee a night gaffer. I attended a nutrition class a couple of years ago that problem came up, the nutritionist suggested eat your evening meal no later than 5pm and no snacks or liquids after your meal, she said this would reduce your washroom trips and might even eliminate them. 
Comment by tamarindo1 on Mar 26, 2021 9:10am
Thank you:  My evening glass of wine forbidden?  No thank you, I'll carry on peeing, at this stage in life small pleasures often overide those things that may improve quality or even life extension. :-) 
Comment by 99942Apophis on Mar 26, 2021 12:59pm
I think that nutritionist might give you a nod of approval tamarindo1
Comment by tdon1229 on Mar 26, 2021 1:13pm
  Next time you visit your doctor/urologist, consider inquiring re using a catheter ... do a self-cath as the last thing each night before bed to completely drain your tank ... even a little bit left from a normal void can result in a premature urge and an extra visit ... my kidneys do their best work while I'm sleeping, but pee o'clock usually only comes once each night after about ...more  
Comment by menoalittle on Mar 26, 2021 1:16pm
hey... sounds a bit like my program... lol. getting old is hard... but far better than the alternative!
Comment by fredgoodwinson on Mar 25, 2021 7:38pm
Thanks CancerSlayer. Information from Phase IB was released inconsistently. Good news came quickly or relatively so but the reason for the long period of silence in the middle - when they hit issues - only became clear in retrospect. Much the same could be said of the period prior to the revelation of the dosing debacle at the start of Phase II. Both intervals ended with the requirement for a ...more  
Comment by CancerSlayer on Mar 25, 2021 8:15pm
  Yep Fred....it can be anxious times during any "perceived" delay.  Fortunately, any perceived delays moving forward should be scientifically measured ones, & not ones due to controllable oversight.   And not only is there Huuuuge incentive for all parties to do their best, our ACT sets a satisfyingly  low bar for patient compliance.  Name that efficacy ...more  
Comment by 99942Apophis on Mar 25, 2021 8:58pm
This isn't meant for long shareholders but for some of the newer ones that once a patient is enrolled there is a 28 days waiting period prior to treatment. This would explain current low numbers state side alone with rising numbers in Covid-19 infections in both countries,  in my opinion.
Comment by enriquesuave on Mar 26, 2021 10:37am
Right on.  I think we will get our 9 more patients by mid May.  Just IMO  
Comment by Bunge on Mar 25, 2021 9:06am
I feel like it's a sports league that announces the schedule and then keeps announcing that games have been played without ever announcing the SCORES.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250